The treatment of unresectable hepatocellular carcinoma (HCC) has radically changed after the approval of the combination of atezolizumab plus bevacizumab as first-line treatment. A strong preclinical rationale exists to support the combination of bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody (mAb), and atezolizumab, an anti-programmed death ligand 1 mAb. The efficacy of the combination was first assessed in the phase Ib GO30140 study, and the combination was then proven superior to the prior standard of care, sorafenib, in the phase III IMbrave150 trial.
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma / D'Alessio, Antonio; Cammarota, Antonella; Zanuso, Valentina; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - 21:9(2021), pp. 927-939. [10.1080/14737140.2021.1948329]
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
Personeni, Nicola;
2021-01-01
Abstract
The treatment of unresectable hepatocellular carcinoma (HCC) has radically changed after the approval of the combination of atezolizumab plus bevacizumab as first-line treatment. A strong preclinical rationale exists to support the combination of bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody (mAb), and atezolizumab, an anti-programmed death ligand 1 mAb. The efficacy of the combination was first assessed in the phase Ib GO30140 study, and the combination was then proven superior to the prior standard of care, sorafenib, in the phase III IMbrave150 trial.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
